Laboratories Inc., Naperville, IL) served as a control. It was mixed as 2 mg/ml in 0.5 ml HBSS. Hybridoma 2.43 ascites was diluted to 2 mg/ml or less in 0.5 ml HBSS.
Fluorescence-activated Cell Sorter Analysis. Flow cytometry analysis of lymphocyte or tumor cell surface phenotypes was carried out by indirect fluorescence using a FACS 440 flow microfluorometer (Becton Dickinson & Co., Mountain View, CA), interfaced with a PDP 11/24 comruter (Digital Equipment Corp., Maynard, MA). Pelleted single cell suspensions of 10 cells were incubated for 45 min at 4°C with 10-30 A1 of mAbs diluted in PBS containing 3 % FCS and 0.1 % NaN3. Bound antibodies were detected by incubation with an appropriately titered FITC-labeled mouse mAb to rat K B16 Clones. BL6-13, CL8-1, and CL8-2 are cell lines derived from murine melanoma B16BL6 subdone 8 by calcium phosphate cotransfection with a pRSVneo plasmid containing the selectable marker gene encoding resistance to neomycin (BL6-13) or both the neomycin resistance plasmid and another pRSV plasmid containing the DNA encoding Kb, a class I antigen (CL8-1, CL8-2) . Line BL22 was derived from B16BL6 Clone 8 by calcium phosphate cotransfection with pRSVneo and another plasmid containing the genes encoding the a and ,B chains of la', a class II antigen (Tanaka, K., and G. Jay, unpublished data). All lines were maintained in continuous culture in DMEM with 10% FCS and passaged twice weekly. Before each experiment, expression of class I antigen on the cell surface was verified with indirect immunofluoresence on the FACS 440, using mAb 28-8-6 .
Generation of LAK Cells. C57 spleen cells in complete medium (CM) were prepared as previously described (11) . 1 ml of CM containing 4 x 106 viable splenocytes was added to each well of a 24-well culture plate (no. 3524, Costar, Cambridge, MA) . 1 ml of CM containing 2,000 U of IL-2 was added to each well. After 3 d of incubation at 37°C with 5% C02, cells were harvested and tested for lytic activity in a 4-h chromium-release assay (11, 16) .
In Vitro Sensitization to Allogeneic Cells. Conditions for allogeneic in vitro sensitization have been described in detail (11) . Briefly, 4 x 106 responder C57 splenocytes and 2 x 106 irradiated (3,000 rad) DBA/2 spleen stimulator cells were cultured in 2 ml of CM in individual wells of a 24-well tissue culture plate (Costar), for 4 d at 37°C with 5% C02. The cells were harvested and tested for cytotoxic activity against tumor or P815 targets in a 4-h chromium-release assay as described (I1, 16). EL-4 targets were specificity controls.
Statistics . Statistical analyses were performed by the Wilcoxon rank sum test (13) . Two-sided p values are presented in all experiments . No mice Were excluded from the statistical evaluations.
Results
Correlation of MCA Sarcoma Class 1 MHC Expression In Vivo with IL-2 Sensitivity. Previous work from our laboratory (4) using four murine sarcomas, all induced by the carcinogen 3-methylcholanthrene, established that high-dose IL-2 immunotherapy mediated 80-90% reduction of 10-d pulmonary macrometastases of weakly immunogenic tumors MCA-105 and -106 but had no effect on macrometastases of nonimmunogenic tumors MCA-101 and -102.
Expression in vivo of class I and II MHC molecules by macrometastases from these four sarcomas was tested by immunoperoxidase staining of frozen sections of lung from mice 10 d after injection with tumor cells. The results in the first panel of Table I show that tumors 105 and 106 stain positively for class I MHC using a murine mAb that identifies Kb. Tumors MCA-101 and -102 show no 2 therapy, we used cell lines derived from a subcloned murine melanoma, B16BL6, that were transfected with either : (a) a plasmid encoding the selectable marker for Neomycin resistance, neo'; (b) class I MHC gene encoding Kb and the neo' plasmid; (c) class II genes Iaa and Ias and the neo' plasmid (Tanaka, K., and G. Jay, unpublished data). These cell lines were designated BL6-13, CL8-2, and BL-22, respectively . A northern blot of RNA from these cell lines is shown in Fig. 2 . Cytoplasmic polyadenylated RNA from the transfected cell lines and control cells was fractionated on agarose-formaldehyde gels. A synthetic oligonucleotide probe specific to the Kb gene was used for hybridization in the left lanes A1-4 of Fig. 2 ; a strong signal in lanes A3 and A4 at 1 .8 kb indicates the presence of class I mRNA in the cell lines CL8-I and CL8-2, two cell lines transfected with the neo' plasmid and the Kb class I gene . In lanes A1 and A2, B16BL6 clone 8 and BL6-13, the parental cell line and the line transfected with the neo' plasmid, do not express detectable class I mRNA. Right lanes B1-B4 show that B16 clone 8, BL6-13, CL8-1, and CL8-2, express normal amounts of actin mRNA as a positive control. A northern blot of cytoplasmic polyadenylated RNA has been performed (Tanaka, K., and G. Jay, unpublished data), showing that BL22, a cell line transfected with neo' plasmid and the genes encoding a and ft chains of Iak, expresses mRNA for both chains .
A microfluorometric flow analysis of the control, class 1, and class II transfectant lines was performed using mAbs recognizing Kb, Iab, and la'. The immu-FIGURE 2. Northern blot of RNA from cell lines B16BL6 clone 8, BL6-13, CL8-1, and CL8-2, from left to right in each panel. Polyadenylated cytoplasmic RNA was obtained from the above cell lines as described (30) , and fractionated on a 1% agarose gel in the presence of formaldehyde. The RNA was transferred from the gel to a nitrocellulose membrane, and the resulting RNA blot was hybridized to '4P-labeled DNA probes for the Kb class I gene (A1-A4) or flactin (BI-B4). Hybridization was at 45°C in 50% formamide, 5X SSC, 5X Denhardt's solution . The arrow on the right indicates the position of the class I transcript at 1 .8 kb.
nofluorescence profiles are shown in Fig . 3 . Control cell line BL6-13 does not bind antibodies 28-8-6 or 34-5-3, indicating that it expresses no class I or II MHC molecules at its surface . CL8-2 binds mAb 28-8-6 but not 34-5-3, indicating that it expresses class I but not class II MHC molecules . BL22 binds mAb 10 .2-16 but not 28-8-6, indicating the presence of class II lak but no syngeneic class I molecules . Immunoperoxidase staining ofpulmonary metastases or subcutaneous tumors generated by BL6-13 or class I transfectant CL8-2 shows positive staining by a class I mAb only for CL8-2 (data not shown) . Therefore, the class I transfectant line CL8-2 transcribes mRNA for K b and expresses the Kb antigen molecule at its surface in vitro and in pulmonary or subcutaneous tumor in vivo . The class II transfectant line BL22 similarly transcribes class II mRNA and expresses the class II molecule at its surface . In contrast, control line BL6-13 neither transcribes mRNA for, nor expresses class I or II MHC molecules .
LAK and Allogeneic CTL Lysis of Transfected Cell Lines. Class I transfectant line CL8-2 and control line BL6-13 were tested for sensitivity to lysis in vitro by syngeneic LAK cells, and by allogeneic CTL . DBA/2 splenocytes sensitized to irradiated C57BL6 splenocytes should lyse allogeneic b haplotype class I-expressing cells, but not cells bearing either syngeneic d haplotype or no class I molecules . LAK cells are generated by 3-d incubation of normal C57BL6 splenocytes in IL-2, and show MHC-unrestricted lysis of many fresh and cultured tumor cell lines in vitro (17) . The top panel of Fig. 4 shows that control line BL6-13 and transfected line CL8-2 are lysed equally by LAK cells in a 4-h chromium-release assay . However, in the bottom panel, allogeneic CTLs lyse class I transfected CL8-2 cells, but not control line BL6-13 . Therefore, the class I molecules expressed on line CL8-2 are functional in an MHC-restricted allogeneic CTL reaction in vitro . LAK lysis in vitro is not an MHC-restricted phenomenon (17) , and LAK cells lyse CL8-2 and BL6-13 equally well . Table 11 , and one experiment is plotted in Fig. 5 . Control BL6-13 micrometastases are sensitive to IL-2 immunotherapy in one of the experiments only at the highest dose of IL-2, 182 vs. 82 metastases, p < 0.05. In contrast, class I transfected CL8-2 micrometastases showed statistically significant and considerable regression at all IL-2 doses, 283 vs. 15 metastases at the highest IL-2 dose in Exp. 1, 201 vs. 17 metastases in Exp. 2. Expression of class I MHC increased crometastatic sensitivity to IL-2 at doses from 10,000 to 100,000 U i.p. every 8 h given for 5 d, beginning 3 d after injection of tumor cells.
Pulmonary macrometastases were generated by intravenous injection of tumor cells from parental line B16BL6, control line BL6-13, and class I transfectant line CL8-2. Table III shows the results of two experiments in which mice received IL-2 therapy from day 10 to day 14 after tumor injection, and lung metastases were counted on day 18 . In neither experiment was there a demonstrable impact of IL-2 therapy on the number of pulmonary macrometastases generated by between BL6-13 and CL8-2 . This result suggests that expression of a class II MHC gene by B16BL6 melanoma cannot induce micrometastatic sensitivity to IL-2 in semisyngeneic F, mice. Lyt-2 Cells Mediate Reduction of CL8-2 Macrometastases by High-dose IL-2. To establish whether an Lyt-2 cell was involved in mediating regression of 10-d pulmonary macrometastases induced by class I transfected line CL8-2, rat antiLyt-2 mAb 2.43 was injected intravenously before the onset of IL-2 immunotherapy to deplete the Lyt-2 lymphocyte subset. After 5 d of IL-2 therapy, the lymphocyte populations were examined to verify Lyt-2 depletion . Fig . 6 shows microfluorometric analyses of splenocytes 5 d after antibody treatment . There is >85% depletion of Lyt-2 + cells in mice treated with mAb 2.43 . As a control, fluorescein-conjugated anti-L3T4 mAb was used to measure the L3T4 lymphocyte subset in mice treated with anti-Lyt-2 mAb or rat Ig-treated control mice. The bottom two panels of Fig . 6 show no change in the L3T4* subset after treatment with mAb 2 .43 . The splenocytes from anti-Lyt-2-treated mice are also unable to generate an allogeneic CTL response in vitro . Splenocytes from C57BL6 mice were removed on day 5 after mAb 2.43 or rat Ig injection, on the last day of IL-2 therapy of CL8-2 macrometastases, and cocultured with irradiated DBA/2 splenocytes for 5 d to generate allogeneic CTLs. The allogeneic CTLs were used as effectors in a 4-h chromium-release assay with tumor line P815 as the target. The results are shown in Fig. 7 . Mice treated with mAb 2.43 fail to generate allogeneic CTL lysis of P815, whereas control mice treated with rat Ig generate good allogeneic CTL killing of P815 in vitro . The results of these microfluorometric and allogeneic CTL assays of in vivo cell depletion are similar at 14 d after mAb injection (Yang, J., personal communication) .
The results of two identical anti-Lyt-2 depletion experiments on the generation of CL8-2 macrometastases treated with high-dose IL-2 are shown in Table V 6 . Flow microfluorometric analysis of splenocytes from mice treated with anti-Lyt-2 mAb 2.43 (left Panels) or control animals treated with rat Ig (right panels). Antibody was administered intravenously '5 d before analysis, as 100 AI of crude ascites suspended in 0.5 m1 HBSS . Spleens were removed and single cell suspensions were generated as described previously (13) . The two left panels show staining profiles of control splenocytes using anti-Lyt-2 and anti-L3T4 FITC antibodies (Becton Dickinson & Co .) . In the right panels, the staining profiles ofanti-Lyt-2-depleted splenocytes are shown. Cell number is measured on theordinate, and fluorescence intensity is measured on the abcissa in arbitrary logarithmic units. A total of 10 6 cells is analyzed in each panel.
ALLO CTL VS. P815 FIGURE 7. Ability of splenocytes from animals treated with anti-Lyt-2 mAb to generate allogeneic CTL in vitro. 5 d after C57BL/6 mice received an intravenous injection of either mAb 2.43 or rat Ig, spleen cells were removed and cultured with irradiated DBA/2 stimulator cells at a ratio of 2:1 for 4 d in RPMI 1640 complete medium . The C57 splenocytes were used as effectors in a 4-h chromium-release assay using "Cr-labeled P815 cells grown in ascites as the allogeneic target . Lysis of control syngeneic target EL-4 was <5% for all effectors (not shown).
vs. 169 for 100 x103 U IL-2, and 53 vs. 28, both significant at p < 0.05) . As seen previously, lower doses of IL-2 do not impact on CL8-2 macrometastases. The effect of high-dose IL-2 on CL8-2 macrometastases in both experiments is completely abrogated in animals treated with anti-Lyt-2 mAb 2.43 (232 for alone, two-sided. $ P < 0.05. § P < 0.005 . All others were not significant. HBSS vs. 247 for 100 kD IL-2, and 61 vs. 55, both not significant). This result suggests that an Lyt-2-bearing cell is involved in the high-dose IL-2-mediated regression of CL8-2 10-d pulmonary metastases.
Lyt-2 Cells Mediate Reduction of CL8-2 Micrometastases by Low-dose, Not Highdose IL-2. To establish whether a Lyt-2-bearing cell mediates regression of 3-d pulmonary micrometastases generated by class I transfected line CL8-2, rat mAb 2.43 was injected intravenously 3 d after tumor cell administration . IL-2 therapy was begun 6 h later and continued every 8 h for 5 d. Lymphocyte populations were examined to verify Lyt-2 depletion as in the prior experiments . Virtually complete depletion was obtained with data similar to that in Figs . 6 and 7 (data not shown). The results of two similar anti-Lyt-2 depletion experiments on the generation of CL8-2 micrometastases treated with varying doses of IL-2 are shown in Table VI . IL-2 at doses ranging from 1-10 x 10' U i.p. every 8 h for 5 d was capable of mediating significant and substantial regression of CL8-2 micrometastases in rat Ig-treated control animals . The regression is invariably (22) 246 (24) 247 (19) 2 Rat Ig 55 (9) 55 (17) 65 (14) 28$ (5) Anti-Lyt-2 61 (7) 56 (14) 77 (11) 53 (6) Exp. greatest at the highest dose of IL-2 (262 vs. 15, and 81 vs. 9, P < 0.005). In antiLyt-2-treated animals, the effect of low-dose IL-2 (1-3 X 10' U) is abrogated, whereas IL-2 at 10 X 10' U still mediates significant regression of CL8-2 micrometastases (268 vs. 37, and 93 vs. 12, p < 0.005). A Lyt-2-bearing cell is involved in low-dose IL-2-mediated regression of CL8-2 micrometastases. In contrast, high-dose IL-2 can mediate significant tumor elimination independent of a Lyt-2-bearing cell. This suggests that CL8-2 micrometastases may be eliminated by at least two mechanisms mediated by IL-2; one involving Lyt-2 cells, and one that does not. Discussion Observations made in our laboratory and others suggest that regression of tumor in animals treated with IL-2 is mediated via the host immune system . The effect of IL-2 can be eliminated in animals treated with doses of radiation that suppress cell-mediated immunity (14) . Similarly, lethally irradiated mice reconstituted with T cell-depleted bone marrow have complete abrogation of the IL-2 antitumor effect (11) . Mule et al. (4) have demonstrated that treatment with high-dose IL-2 can mediate regression of 3-d pulmonary micrometastases from weakly immunogenic and nonimmunogenic sarcomas . Lyt-2+, as well as asialo GM1' cells, were involved in regression of immunogenic tumors, though only asialo GM 1' cells were involved in IL-2-mediated regression of nonimmunogenic 3-d tumors . 10-d pulmonary macrometastases from immunogenic tumors were susceptible to therapy with high-dose IL-2, but macrometastases from nonimmunogenic tumors were not. An Lyt-2-bearing cell was involved in the regression of macrometastases from these weakly immunogenic sarcomas . L3T4-bearing cells were not involved in the regression of micro-or macrometastases from either non-or weakly immunogenic sarcomas treated with IL-2. These data indicated that Lyt-2+ cells are intermediaries in IL-2 immunotherapy of weakly immunogenic sarcomas .
Since the presence of Lyt-2, a murine T cell marker, determines both cytolytic function and class I MHC associated recognition of antigen (5) (8) (9) (10) . Similarly, many human tumors appear to be class I deficient, such as neuroblastomas (19) , basal cell carcinomas (20) , small cell lung tumors (21), or choriocarcinomas (22) .
Modulation of class I expression on murine tumor cells by gene transfection has been shown to reverse oncogenesis (9), decrease metastatic capability (8) , and potentiate immunogenicity (7, 10) . Oncogenic strains of adenoviruses and retroviruses have evolved mechanisms to selectively downregulate MHC class I expression (23, 24) . Reduced class I expression may represent a mechanism for tumor cells to evade destruction by cellular immunity, and may be an integral feature of oncogene-mediated cellular transformation (25) .
As we have shown, IL-2 mediates regression of advanced weakly immunogenic sarcoma metastases via a Lyt-2' T cell, and cannot impact on advanced metastases from nonimmunogenic sarcomas (4) . Since interaction of Lyt-2' cells with tumor cells seemed necessary for the immunotherapeutic effect of IL-2 on advanced sarcoma metastases, we hypothesized that decreased sensitivity to IL-2 therapy would correlate with attenuated expression of class I MHC . Upregulation of class I should promote T cell-mediated tumor recognition and result in an increased sensitivity to IL-2 immunotherapy.
In accord with this hypothesis, the experiments presented herein show that weakly immunogenic tumors MCA-105 and -106 express class I MHC molecules in vivo and in vitro and are susceptible to therapy with high-dose IL-2; nonimmunogenic tumors 101 and 102 express little or no class I MHC in vivo or in vitro and advanced metastases are not sensitive to IL-2 therapy. None of the four tumors express class II MHC antigens . A murine melanoma that expressed minimal class I MHC was subcloned and transfected with genes encoding class I molecule Kb or class II molecule lak (Tanaka, K., and G. Jay, unpublished data). Expression of class I MHC significantly increased the sensitivity of advanced 10-d metastases from the B16 transfectant tumor to IL-2 therapy. A more impressive increase in IL-2 susceptibility was seen when treating 3-d pulmonary micrometastases . Lower doses of IL-2, which did not cause regression of B16 transfectant 10-d macrometastases, strongly impacted on micrometastases .
Using in vivo antibody depletion to eliminate Lyt-2-bearing cells from treated mice, we have shown that high-dose IL-2-mediated regression of B16 transfectant macrometastatic tumor involves an Lyt-2' cell, possibly a tumor-specific cytolytic T cell. Two cell types appear to be involved in the regression of B16 transfectant 3-d micrometastases . At low doses of IL-2 the predominant cell appears to be Lyt-2' . However, at higher doses of IL-2, regression of micrometastases can also be mediated by Lyt-2-cells, presumably LAK cells. These findings are in accordance with the work of Mule et al. (4) , in which weakly immunogenic sarcoma macrometastases, shown in this paper to express class I MHC were susceptible to IL-2 therapy, whereas nonimmunogenic sarcoma macrometastases shown herein to be devoid of class I MHC, were not susceptible to IL-2 therapy.
We thus postulate a model for IL-2-mediated antitumor effects in which Lyt- The effects of IL-2 on advanced murine macrometastases are analogous with the immunotherapy of advanced cancer in humans. High-dose IL-2 alone or with the concurrent administration of LAK cells has been shown to be capable of causing significant objective tumor responses and a modest number of complete responses in a variety of human malignancies (26) . Many tumors, however, remain resistant to IL-2 immunotherapy. Since advanced murine tumors that express class I MHC are more sensitive to IL-2 therapy, the patients whose tumors show no objective response to IL-2 may be deficient in class I expression at one or more of the HLA-A, -B, or -C loci. Ample evidence exists for downregulation of HLA class I loci in human tumors (22) (23) (24) . We plan to assay levels of HLA-A, -B, or -C expression in tumors before IL-2 therapy to ask whether the level of class I expression predicts a response to IL-2 . If this is true then patient tumor cell MHC modulation in vitro can be attempted using IFN-a or -y or TNF-a, molecules known for their ability to upregulate HLA expression in human cells (27) (28) (29) . Lymphocytes sensitized in vitro to tumor-expressing class I MHC may show increased antitumor activity after adoptive transfer .
Summary
We have shown that two weakly immunogenic MCA sarcomas developed in our laboratory that are sensitive to high-dose IL-2 immunotherapy express class I MHC in vivo and in vitro. Two nonimmunogenic MCA sarcomas are relatively insensitive to IL-2 therapy and express minimal or no class I MHC molecules in vivo and in vitro . To study the role of MHC in the therapy of tumors with IL-2, a class I-deficient murine melanoma, B16BL6, was transfected with the Kb class I gene . Expression of class I MHC rendered B16BL6 advanced pulmonary macrometastases sensitive to IL-2 immunotherapy. 3-d micrometastases of CL8-2, a class I transfected clone of B16BL6, were significantly more sensitive to IL-2 therapy than a control nontransfected line . Expression of la', a class II MHC molecule, had no effect on IL-2 therapy of transfectant pulmonary micrometastases in F, mice . By using lymphocyte subset depletion with mAbs directed against Lyt-2, therapy of class I transfectant macrometastases with high-dose IL-2 was shown to involve an Lyt-2 cell. In contrast, regression of micrometastases treated with low-dose IL-2 involved Lyt-2' cells, but regression mediated by high doses of IL-2 did not. We hypothesize that both LAK and Lyt-2' T cells effect 1L-2-mediated elimination of micrometastases, but only Lyt-2' T cells are involved in macrometastatic regression. Low doses of IL-2 stimulate Lyt-2+ cells to eliminate class I-expressing micrometastases, but high doses of IL-2 can recruit LAK cells to mediate regression of micrometastases independent of class I expression . Only high-dose IL-2, mediating its effect predominantly via Lyt-2' cells, is capable of impacting on MHC class I-expressing macrometastases . Macrometastases devoid of class 1 MHC antigens appear to be resistant to IL-2 therapy .
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